Clinical Trial Update: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a galantamine and memantine combination for cognitive impairments in schizophrenia was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Galantamine (galantamine)
• Memantine (memantine)

Snippet

Sponsor: Sheppard Pratt Health System | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: TERMINATED | Results posted: 2017-11-09